Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
SWS Hemodialysis Care Co's 3-Year RORE % for the quarter that ended in Mar. 2026 was 4.24%.
The industry rank for SWS Hemodialysis Care Co's 3-Year RORE % or its related term are showing as below:
SHSE:688410's 3-Year RORE % is ranked better than 59.28% of 776
companies
in the Medical Devices & Instruments industry
Industry Median: -3.855
vs SHSE:688410: 4.24
SWS Hemodialysis Care Co (SHSE:688410) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
SWS Hemodialysis Care Co 3-Year RORE % Related Terms
SWS Hemodialysis Care Co 3-Year RORE % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688410 vs ISRG, BDX, MDLN: 3-Year RORE % Comparison
For the Medical Instruments & Supplies subindustry, SWS Hemodialysis Care Co's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SWS Hemodialysis Care Co 3-Year RORE % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, SWS Hemodialysis Care Co's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where SWS Hemodialysis Care Co's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2026 and 3-year before.
SWS Hemodialysis Care Co (SHSE:688410) has a 3-Year RORE % of 4.24 as of Mar. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on SWS Hemodialysis Care Co and its competitors. According to the industry distribution chart, SWS Hemodialysis Care Co ranks #316 out of 776 companies in the Medical Devices & Instruments industry, placing it in the top 40.7%.
Is SWS Hemodialysis Care Co's 3-Year RORE % too high?
SWS Hemodialysis Care Co's current 3-Year RORE % is 4.24. Based on the distribution chart, SWS Hemodialysis Care Co ranks #316 out of 776 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, SWS Hemodialysis Care Co has a GF Score™ of 89/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SWS Hemodialysis Care Co's 3-Year RORE % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, SWS Hemodialysis Care Co ranks #316 out of 776 companies for 3-Year RORE %. This puts SWS Hemodialysis Care Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on SWS Hemodialysis Care Co and its competitors. SWS Hemodialysis Care Co's current 3-Year RORE % is 4.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SWS Hemodialysis Care Co stock overvalued right now?
Based on GuruFocus' analysis, SWS Hemodialysis Care Co (SHSE:688410) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥15.62, compared to a current price of ¥11.20 — trading 28.3% below its estimated fair value. The current 3-Year RORE % is 4.24. SWS Hemodialysis Care Co's overall GF Score™ is 89/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For SWS Hemodialysis Care Co (SHSE:688410), the current 3-Year RORE % is 4.24 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SWS Hemodialysis Care Co (SHSE:688410) Overvalued in 2026?
Based on GuruFocus' analysis, SWS Hemodialysis Care Co stock appears to be undervalued.
The current stock price of ¥11.20 is trading 28.3% below its estimated GF Value™ of ¥15.62.
GuruFocus considers SWS Hemodialysis Care Co to be Modestly Undervalued.
Key valuation signals for SHSE:688410:
3-Year RORE %: 4.24
GF Value™: ¥15.62 vs. price of ¥11.20 (28.3% below fair value)
No single metric tells the full story. See the SHSE:688410 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SWS Hemodialysis Care Co Ltd along with its subsidiaries is engaged in the field of blood purification. Its focused on patients welfare and ensuring the delivery of safe and effective products and services. The group operates through four segments: Blood Purification Equipment, Blood Purification Consumables, advanced Hemodialysis Management System, and Chain Dialysis centers. The organization is delivering medical solutions for patients with chronic kidney disease (CKD). Its products include Blood Purification Equipment Dialysis, Disposables Dialysis Center, Intelligent Management System, and Chain Dialysis centers. SWS is committed to enhancing patient wellness by prioritizing care through advanced integrated blood purification technologies.
89GF Score
Get the complete analysis for SHSE:688410
3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688410 has been successfully added to your 
